The ethical use of mandatory research biopsies

Nature Reviews Clinical Oncology

Volumn 8, Issue 10, 2011, Pages 620-625

  Olson, Erin M ^a   Lin, Nancy U ^a   Krop, Ian E ^a   Winer, Eric P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BIOLOGICAL MARKER; ERLOTINIB; GEFITINIB; KI 67 ANTIGEN; LAPATINIB; NAVELBINE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CLINICAL DECISION MAKING; GENE; GENE EXPRESSION PROFILING; HER2 GENE; HUMAN; INFORMED CONSENT; LUNG BIOPSY; LUNG CANCER; MANDATORY TESTING; MET GENE; MOLECULARLY TARGETED THERAPY; PATIENT AUTONOMY; PATIENT CARE; PATIENT SAFETY; PNEUMOTHORAX; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RESEARCH ETHICS; REVIEW; STANDARDIZATION; TUMOR BIOPSY; TUMOR GROWTH;

BIOMEDICAL RESEARCH; BIOPSY; CLINICAL TRIALS AS TOPIC; HUMANS; INFORMED CONSENT;

EID: 80053569318     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.114     Document Type: Review

References (45)

1. Mandrekar, S. J. & Sargent, D. J. Genomic advances and their impact on clinical trial design. Genome Med. 1, 69 (2009).
2. Mandrekar, S. J. & Sargent, D. J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol. 27, 4027-4034 (2009).
3. Mandrekar, S. J. & Sargent, D. J. Clinical trial designs for predictive biomarker validation: one size does not fit all. J. Biopharm. Stat. 19, 530-542 (2009).
4. Peppercorn, J., et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J. Clin. Oncol. 28, 2635-2640 (2010).
5. Slamon, D. J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001). (Pubitemid 32222155)
6. Kwak, E. L., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
7. Tsao, M. S., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
8. van Cutsem, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
9. Demetri, G. D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002). (Pubitemid 34879334)
10. Sørlie, T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001). (Pubitemid 32878711)
11. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01042379.
12. Locatelli, M. A., et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? J. Clin. Oncol. Annual Meeting Proceedings (Post-Meeting Edition). 28 (2010).
13. Berney, D. M., Montironi, R. & Egevad, L. Pathology in prostate research: optimizing tissue quality. Acta Oncol. 50 (Suppl. 1), 53-55 (2011).
14. Harris, L. N., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13, 1198-1207 (2007). (Pubitemid 46424061)
15. Krop, I. & Winer, E. Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Res. Treat. 113, 207-209 (2009).
16. Shapiro, G., et al. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors [abstract 3500]. J. Clin. Oncol. 25 (2009).
17. Dowsett, M., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 99, 167-170 (2007).
18. Winer, E. What can we learn? The scientific justification for consideration of mandatory research biopsy within some clinical trials. ASCO Annual Meeting (Chicago, IL, 2010).
19. Turke, A. B., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88 (2010).
20. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01121575 (2010).
21. Brown, A., Wendler, D., Camphausen, K., Miller, F. & Citrin, D. Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations. J. Clin. Oncol. 26, 3987-3994 (2008).
22. Dowlati, A., et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin. Cancer Res. 7, 2971-2976 (2001). (Pubitemid 32963813)
23. Agulnik, M., Oza, A., Pond, G. & Siu, L. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J. Clin. Oncol. 24, 4801-4807 (2006). (Pubitemid 46655611)
24. Kim, E., et al. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer [abstract LB-1]. Proc. 101st Annual Meeting of the AACR. (Washington, DC, 2010).
25. Nazarian, L. N., et al. Safety and efficacy of sonographically guided random core biopsy for diffuse liver disease. J. Ultrasound Med. 19, 537-541 (2000).
26. Helft, P. & Daugherty, C. Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J. Clin. Oncol. 24, 4793-4795 (2006). (Pubitemid 46630904)
27. Cannistra, S. Performance of biopsies in clinical research. J. Clin. Oncol. 25, 1454-1455 (2007).
28. US Department of Health and Human Services. Protection of Human Subjects. Code Fed. Regul. Public Welfare. Title 45 (Section 46). (2005).
29. Weinfurt, K. P., et al. Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med. Decis. Making 28, 575-581 (2008). (Pubitemid 351990000)
30. Wright, J. R., et al. Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J. Clin. Oncol. 22, 4312-4318 (2004). (Pubitemid 41185152)
31. Catania, C., et al. Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. Oncology 74, 177-187 (2008).
32. Nurgat, Z. A., et al. Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br. J. Cancer 92, 1001-1005 (2005). (Pubitemid 40546660)
33. Stadtmauer, E. A., et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N. Engl. J. Med. 342, 1069-1076 (2000). (Pubitemid 30207689)
34. Joffe, S., et al. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet 358, 1772-1777 (2001). (Pubitemid 33153003)
35. Flory, J. & Emanuel, E. Interventions to improve research participantsunderstanding in informed consent for research: a systematic review. JAMA 292, 1593-1601 (2004). (Pubitemid 39314966)
36. Katz, M. Are we asking too much? Ethical concerns over mandatory research biopsy: concerns over coercion. ASCO Annual Meeting (Chicago, IL, 2010).
37. Brown, R. F., Butow, P. N., Butt, D. G., Moore, A. R. & Tattersall, M. H. Developing ethical strategies to assist oncologists in seeking informed consent to cancer clinical trials. Soc. Sci. Med. 58, 379-390 (2004). (Pubitemid 37353050)
38. Joffe, S. & Weeks, J. C. Views of American oncologists about the purposes of clinical trials. J. Natl Cancer Inst. 94, 1847-1853 (2002). (Pubitemid 36104629)
39. Kerick, M., Timmermann, B. & Schweiger, M. R. [High-throughput sequencing of frozen and paraffin-embedded tumor and normal tissue]. Pathologe 31, 255-257 (2010).
40. Hillman, B. J. & Goldsmith, J. C. The uncritical use of high-tech medical imaging. N. Engl. J. Med. 363, 4-6 (2010).
41. Kuang, Y., et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin. Cancer Res. 15, 2630-1636 (2009).
42. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01185509.
43. US National Library of Medicine ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00820924.
44. Emanuel, E., Wendler, D. & Grady, C. What makes clinical research ethical? JAMA 283, 2701-2711 (2000). (Pubitemid 30337334)
45. Agrawal, M. & Emanuel, E. Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA 290, 1075-1082 (2003). (Pubitemid 37430449)